Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Tartisan Nickel Corp. Intersects 11.0 Metres of 1.05% Ni, 0.33% Cu Including 2.0 Metres of 4.79% Ni, 1.25% Cu at the Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario
Mayfair Gold Presents the Initial Results from the 2025 Grade Control Drilling Program at the Fenn-Gib Project
